Higher doses of buprenorphine are essential for effective addiction treatment, particularly amid the fentanyl crisis, yet access is hampered by state-imposed Medicaid dosages.
Ryan Alexander highlights that limitations in Medicaid reimbursement for buprenorphine mean many patients face heightened relapse risks, especially when cravings remain uncontrolled.
The opioid crisis necessitates reassessing current restrictions on buprenorphine dosing; with fentanyl's potency rising, higher dosages could drastically impact patient outcomes.
Research shows that arbitrary dosing limits may be detrimental to patients' treatment, particularly when combating powerful synthetic opioids like fentanyl.
#opioid-addiction #buprenorphine-dosing #medicaid-regulations #fentanyl-crisis #substance-use-treatment
Collection
[
|
...
]